Trevena Inc (NASDAQ:TRVN) saw a significant decline in short interest in the month of October. As of October 31st, there was short interest totalling 8,481,679 shares, a decline of 41.2% from the October 15th total of 14,428,796 shares. Currently, 14.2% of the company’s shares are short sold. Based on an average daily volume of 3,940,966 shares, the short-interest ratio is presently 2.2 days.
TRVN has been the subject of a number of analyst reports. Zacks Investment Research raised shares of Trevena from a “hold” rating to a “buy” rating and set a $0.75 target price for the company in a research note on Thursday. HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of Trevena in a research note on Monday, August 13th. Needham & Company LLC downgraded shares of Trevena from a “buy” rating to a “hold” rating in a research note on Friday, October 12th. Jefferies Financial Group downgraded shares of Trevena from a “buy” rating to a “hold” rating and lowered their target price for the stock from $10.00 to $1.00 in a research note on Wednesday, October 10th. Finally, JMP Securities lifted their target price on shares of Trevena from $4.00 to $15.00 and gave the stock an “outperform” rating in a research note on Friday, October 12th. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Trevena currently has a consensus rating of “Buy” and a consensus price target of $5.42.
Shares of NASDAQ TRVN opened at $0.66 on Friday. Trevena has a twelve month low of $0.55 and a twelve month high of $3.58. The firm has a market cap of $47.17 million, a P/E ratio of -0.54 and a beta of 0.61. The company has a quick ratio of 3.40, a current ratio of 3.40 and a debt-to-equity ratio of 0.28.
Trevena (NASDAQ:TRVN) last announced its earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.07. The firm had revenue of $3.00 million for the quarter, compared to the consensus estimate of $3.00 million. On average, research analysts predict that Trevena will post -0.55 EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently made changes to their positions in TRVN. BlackRock Inc. raised its stake in Trevena by 151.4% during the third quarter. BlackRock Inc. now owns 1,873,311 shares of the biopharmaceutical company’s stock worth $3,971,000 after buying an additional 1,128,041 shares during the last quarter. FMR LLC increased its stake in Trevena by 24.0% in the second quarter. FMR LLC now owns 5,288,100 shares of the biopharmaceutical company’s stock valued at $7,615,000 after purchasing an additional 1,022,830 shares in the last quarter. Millennium Management LLC increased its stake in Trevena by 112.3% in the second quarter. Millennium Management LLC now owns 1,005,820 shares of the biopharmaceutical company’s stock valued at $1,448,000 after purchasing an additional 532,129 shares in the last quarter. Renaissance Technologies LLC increased its stake in Trevena by 264.1% in the second quarter. Renaissance Technologies LLC now owns 521,700 shares of the biopharmaceutical company’s stock valued at $751,000 after purchasing an additional 378,400 shares in the last quarter. Finally, Paloma Partners Management Co bought a new stake in Trevena in the second quarter valued at $411,000. 42.33% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “Trevena Inc (TRVN) Short Interest Update” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/11/10/trevena-inc-trvn-short-interest-update.html.
Trevena Company Profile
Trevena, Inc, a biopharmaceutical company, develops therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. Its product candidates include OLINVO injection, a G protein biased ligand of the µ opioid receptor that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is preferred; TRV250, a G protein biased ligand targeting the d-receptor, which is in Phase I clinical study for the treatment of migraine; and TRV734, a small molecule G protein biased ligand of the µ opioid receptor that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain, as well as TRV027 for the treatment of acute heart failure.
Recommended Story: Stock Symbol
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.